[144] Takeda Pharmaceutical Company Limited American SEC Filing

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating the planned sale of 52,649 American Depositary Shares (ADSs) through Interactive Brokers.

• Aggregate market value: US$811,847.58
• Percentage of shares outstanding: ~0.04% of the company’s 123,490,548 ADSs outstanding
• Approximate sale date: 09 July 2025
• Security class: American Depositary Shares listed on the NYSE
• Acquisition source: The shares derive from restricted stock unit (RSU) awards that vested on 01 July 2025
• No prior sales were reported by the same holder during the preceding three-month period

The filing does not disclose the name of the selling shareholder, but Rule 144 requires that the seller affirm they possess no undisclosed material adverse information regarding Takeda. Because the volume represents a very small fraction of total outstanding ADSs, the transaction is unlikely to exert material pressure on the stock price. Nevertheless, investors often monitor Form 144 notices as early signals of insider disposition activity and potential sentiment shifts.

Positive

• Minimal dilution risk: Sale represents only ~0.04% of Takeda’s ADSs outstanding, unlikely to affect share supply-demand dynamics.
• Transparent disclosure: Filing provides advance notice, allowing the market to digest the information before the sale date.

Negative

• Insider selling signal: Any planned disposition by an insider can be interpreted as a potential soft negative for sentiment, even if small in value.

Insights

Financial Analyst

TL;DR: Small insider sale (~0.04% of shares) worth US$0.8 M; limited market impact but signals planned disposition.

The proposed sale of 52,649 ADSs is modest relative to Takeda’s float, implying negligible dilution or liquidity impact. The shares stem from recently vested RSUs, suggesting the holder may simply be monetising compensation rather than expressing a bearish view. Absence of prior sales in the last quarter and the mandated certification that no undisclosed adverse information exists further limit negative inference. Overall, this Form 144 is a routine compliance disclosure with neutral implications for most investors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	52649	811847.58	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			113032	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144?

The filing covers 52,649 ADSs to be sold.

What is the total market value of the proposed Takeda share sale?

The aggregate market value is US$811,847.58.

When is the approximate sale date for the Takeda ADSs?

The shares are expected to be sold on or around 09 July 2025.

What percentage of Takeda’s outstanding ADSs does this sale represent?

Roughly 0.04% of the company’s 123,490,548 ADSs outstanding.

Where will the Takeda ADSs be sold and through which broker?

They will be sold on the NYSE via Interactive Brokers LLC.

How were the shares acquired by the seller?

The ADSs originated from restricted stock unit awards that vested on 01 July 2025.